**Supplementary Table 5**: **Risk of bias of randomised controlled trials (RCT)**

| **Study** | **Domain 1** | **Domain 2** | **Domain 3** | **Domain 4** | **Domain 5** | **Domain 6** | **Domain 7** | **Domain 8** | **Overall ROB** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Asante 20201 | low | low | high | high | high | high | low | low | **High** |
| Belmusto-Worn 20052 | unclear | low | low | low | low | high | unclear | low | **Unclear** |
| Camacho 20043 | low | low | low | low | high | low | low | low | **Low** |
| Campi-Azevedo 20144 | unclear | unclear | unclear | unclear | unclear | low | low | low | **Unclear** |
| Chan 20165 | unclear | unclear | high | high | high | low | low | low | **High** |
| Collaborative Group for Studies of Yellow Fever Vaccine 20156 | low | low | low | low | low | low | low | low | **Low** |
| Coursaget 19957 | unclear | unclear | unclear | unclear | unclear | high | unclear | unclear | **High** |
| Edupuganti 20138 | unclear | high | unclear | unclear | high | low | low | unclear | **High** |
| Guirakhoo 20069 | unclear | high | low | unclear | high | low | low | low | **High** |
| Juan-Giner 202110 | low | low | low | high | low | low | low | low | **Low** |
| Lang 199911 | unclear | unclear | low | low | low | high | low | low | **Unclear** |
| Lopez 201612 | low | low | low | low | low | high | low | low | **High** |
| Monath 200213 | unclear | unclear | unclear | unclear | unclear | high | unclear | low | **Unclear** |
| Nasveld 201014 | low | high | high | high | high | high | unclear | low | **High** |
| Novartis 201115 | unclear | unclear | high | high | low | low | low | low | **High** |
| Osei-Kwasi 200116 | unclear | low | low | unclear | high | high | low | low | **High** |
| Roukens 200817 | low | low | unclear | high | unclear | low | unclear | low | **Low** |
| Stefano 199918 | unclear | high | high | high | high | low | low | low | **High** |
| See Supplementary XX for details of ROB tool. Briefly, domain 1 (randomisation), domain 2 (allocation concealment), domain 3 (participant blinding), domain 4 (personnel blinding), domain 5 (assessor blinding), domain 6 (data completeness), domain 7 (selective reporting), domain 8 (other biases).RCT = randomised controlled trial; ROB = risk of bias |

**Supplementary Table 6: Risk of bias of non-randomised studies (Non-RCT and single arm studies)**

| **Study** | **Domain 1** | **Domain 2** | **Domain 3** | **Domain 4** | **Domain 5** | **Domain 6** | **Domain 7** | **Domain 8** | **Domain 9** | **Overall ROB** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Non-randomised comparative studies** |
| Avelino-Silva 2016a19 | yes | unclear | unclear | yes | yes | yes | yes | yes | yes | **Unclear** |
| Avelino-Silva 2016b20 | yes | no | unclear | yes | no | unclear | yes | yes | NA | **High** |
| Burkhard 201021 | yes | unclear | unclear | yes | no | yes | yes | yes | yes | **High** |
| Campi-Azevado 201622 | yes | unclear | yes | no | yes | yes | yes | yes | yes | **High** |
| Collaborative Group for Studies of Yellow Fever Vaccine 2019a23 | yes | yes | yes | unclear | unclear | yes | yes | yes | unclear | **Unclear** |
| Collaborative Group for Studies of Yellow Fever Vaccine 2019b24 | yes | yes | yes | no | yes | yes | yes | yes | yes | **High** |
| De Verdiere 201825 | yes | no | yes | yes | yes | yes | yes | yes | yes | **High** |
| Kernéis 201326 | yes | yes | yes | yes | yes | yes | yes | yes | yes | **Low** |
| Michel 201527 | yes | yes | yes | yes | no | yes | yes | yes | yes | **High** |
| Project RETRO-CI28 | yes | NA | NA | no | yes | no | yes | no | NA | **High** |
| Roukens 201129 | yes | unclear | yes | yes | yes | yes | yes | yes | yes | **Unclear** |
| Valim 202030 | yes | yes | yes | yes | yes | yes | yes | yes | yes | **Low** |
| **Single arm studies** |
| Campi-Azevado 201931 | yes | NA | NA | no | yes | unclear | yes | yes | yes | **High** |
| Domingo 201932 | yes | yes | unclear | no | no | no | yes | yes | yes | **High** |
| Idoko 202033 | yes | yes | NA | no | no | unclear | yes | yes | NA | **High** |
| Jia 201934 | yes | NA | NA | no | yes | yes | yes | yes | yes | **High** |
| Kareko 201835 | yes | NA | NA | no | no | unclear | yes | yes | NA | **High** |
| Veit 201836 | yes | yes | yes | NA | NA | yes | yes | yes | no | **High** |
| See Supplementary XX for details of ROB tool for non-randomised studies. Briefly, domain 1 (clarity of ‘cause’ and ‘effect’), domain 2 (comparison similarities), domain 3 (comparisons of similar treatments), domain 4 (control group), domain 5 (multiple measurements pre and post), domain 6 (follow up), domain 7 (similarity of outcome measures), domain 8 (measurement reliability), domain 9 appropriate statistical analysis).NA = not applicable; ROB = risk of bias |

**References**

[1] Asante KP, Ansong D, Kaali S, Adjei S, Lievens M, Nana Badu L, et al. Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: a phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial. *Vaccine* 2020;38(18):3411-21.

[2] Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. *Am J Trop Med Hyg* 2005;72(2):189-97.

[3] Camacho LAB, Freire Mda S, Leal Mda L, de Aguiar SG, do Nascimento JP, Iguchi T, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. *Rev Saude Publica* 2004;38(5):671-8.

[4] Campi-Azevedo AC, de Almeida Estevam P, Coelho-Dos-Reis JG, Peruhype-Magalhaes V, Villela-Rezende G, Quaresma PF, et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline. *BMC Infect Dis* 2014;14:391.

[5] Chan KR, Wang X, Saron WAA, Gan ES, Tan HC, Mok DZL, et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. *Nat Microbiol* 2016;1:16164.

[6] Collaborative Group for Studies of Yellow Fever Vaccine. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. *Mem Inst Oswaldo Cruz* 2015;110(6):771-80.

[7] Coursaget P, Fritzell B, Blondeau C, Saliou P, Diop-Mar I. Simultaneous injection of plasma-derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. *Vaccine* 1995;13(1):109-11.

[8] Edupuganti S, Eidex RB, Keyserling H, Akondy RS, Lanciotti R, Orenstein W, et al. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity. *Am J Trop Med Hyg* 2013;88(1):172-7.

[9] Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. *Hum Vaccin* 2006;2(2):60-7.

[10] Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, et al. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. *Lancet* 2021;397(10269):119-27.

[11] Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. *Am J Trop Med Hyg* 1999;60(6):1045-50.

[12] Lopez P, Lanata CF, Zambrano B, Cortes M, Andrade T, Amemiya I, et al. Immunogenicity and safety of yellow fever vaccine (Stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12-13 months of age in Colombia and Peru: a randomized trial. *Pediatr Infect Dis J* 2016;35(10):1140-7.

[13] Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. *Am J Trop Med Hyg* 2002;66(5):533-41.

[14] Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, et al. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. *Hum Vaccin* 2010;6(11):906-14.

[15] Novartis Vaccines and Diagnostics S.r.l. Study to evaluate the safety and immunogenicity of travel vaccines when administered concomitantly with meningococcal ACWY conjugate vaccine in healthy adults. EUCTR2011-000475-14-DE. In: WHO International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization (WHO). 2011 [accessed 02.11.20]. Available from: <https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000475-14>

[16] Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK. Antibody response to 17D yellow fever vaccine in Ghanaian infants. *Bull World Health Organ* 2001;79(11):1056-9.

[17] Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. *PLoS One* 2008;3(4):e1993.

[18] Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, et al. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. *Vaccine* 1999;17(9-10):1042-6.

[19] Avelino-Silva VI, Miyaji KT, Hunt PW, Huang Y, Simoes M, Lima SB, et al. CD4/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. *PLoS Negl Trop Dis* 2016;10(12):e0005219.

[20] Avelino-Silva VI, Miyaji KT, Mathias A, Costa DA, de Carvalho Dias JZ, Lima SB, et al. CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients. *J Acquir Immune Defic Syndr* 2016;71(2):189-95.

[21] Burkhard J, Ciurea A, Gabay C, Hasler P, Muller R, Niedrig M, et al. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. *Vaccine* 2020;38(19):3610-7.

[22] Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. *Hum Vaccin Immunother* 2016;12(2):491-502.

[23] Collaborative Group for Studies on Yellow Fever Vaccines. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine. *Vaccine* 2019;37(35):5135.

[24] Campi-Azevedo AC, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, Antonelli LR, Costa-Pereira C, Speziali E, et al. 17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil. *Emerg Infect Dis* 2019;25(8):1511-21.

[25] Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, et al. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. *AIDS* 2018;32(16):2291-9.

[26] Kerneis S, Launay O, Ancelle T, Iordache L, Naneix-Laroche V, Mechai F, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. *Arthritis care & research* 2013;65(9):1522-8.

[27] Michel R, Berger F, Ravelonarivo J, Dussart P, Dia M, Nacher M, et al. Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines? *Vaccine* 2015;33(20):2301-6.

[28] Sibailly TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. *Pediatr Infect Dis J* 1997;16(12):1177-9.

[29] Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. *PLoS One* 2011;6(12):e27753.

[30] Valim V, Machado KLLL, Miyamoto ST, Pinto AD, Rocha PCM, Serrano EV, et al. Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: a prospective non-interventional study. *Front Immunol* 2020;11:1382.

[31] Campi-Azevedo AC, Reis LR, Peruhype-Magalhaes V, Coelho-Dos-Reis JG, Antonelli LR, Fonseca CT, et al. Short-lived immunity after 17DD yellow fever single dose indicates that booster vaccination may be required to guarantee protective immunity in children. *Front Immunol* 2019;10:2192.

[32] Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, et al. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. *Lancet Infect Dis* 2019;19(12):1363-70.

[33] Idoko OT, Domingo C, Tapia MD, Sow SO, Geldmacher C, Saathoff E, et al. Serological protection 5-6 years post vaccination against yellow fever in African infants vaccinated in routine programmes. *Front Immunol* 2020;11:577751.

[34] Jia Q, Jia C, Liu Y, Yang Y, Qi J, Tong L, et al. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa. *Antiviral Res* 2019;162:1-4.

[35] Kareko BW, Booty BL, Nix CD, Lyski ZL, Slifka MK, Amanna IJ, et al. Persistence of neutralizing antibody responses among yellow fever virus 17D vaccinees living in a nonendemic setting. *J Infect Dis* 2020;221(12):2018-25.

[36] Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Hequet D, et al. Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule. *Clin Infect Dis* 2018;66(7):1099-108.